May 06, 2021 09:09 AM (GMT+8) · EqualOcean
Today, Dehong capital (DCP) announced the completion of round B investment in Hangzhou Dejin Medical Technology Co., Ltd., a subsidiary of DeNO medical group. The financing amounts to several hundred million US dollars, which will be mainly used for the company's technological innovation and product development in the treatment of mitral and tricuspid valve diseases. This round of investment is led by Dehong capital and Sequoia China, followed by Qiming medical, Qiming venture capital, Qingchi capital, Guoshou health fund and Jishi capital.

This text is a result of machine translation.